Matthew Sykes
Stock Analyst at Goldman Sachs
(3.82)
# 711
Out of 5,006 analysts
205
Total ratings
50.7%
Success rate
8.86%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $9.59 | -47.86% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.02 | -25.37% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $12.64 | -48.58% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $36.46 | +23.42% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $7.99 | +0.13% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $31.85 | +50.71% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.22 | +4.81% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $190.43 | -15.98% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $9.10 | +9.89% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $93.38 | +33.86% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $14.09 | -0.64% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $211.71 | +13.36% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $14.96 | +73.80% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $174.95 | -2.83% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $63.38 | -11.64% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $120.19 | -33.44% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.52 | -1.32% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $170.38 | +11.52% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.87 | +102.29% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.12 | +36.22% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $36.04 | +2.66% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $57.63 | +12.79% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $205.02 | +21.94% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.88 | +308.16% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,345.27 | -3.37% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $14.87 | -19.30% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $543.95 | +17.66% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $141.61 | +2.39% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $46.96 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $9.59
Upside: -47.86%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.02
Upside: -25.37%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $12.64
Upside: -48.58%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $36.46
Upside: +23.42%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $7.99
Upside: +0.13%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $31.85
Upside: +50.71%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.22
Upside: +4.81%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $190.43
Upside: -15.98%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $9.10
Upside: +9.89%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $93.38
Upside: +33.86%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $14.09
Upside: -0.64%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $211.71
Upside: +13.36%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $14.96
Upside: +73.80%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $174.95
Upside: -2.83%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $63.38
Upside: -11.64%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $120.19
Upside: -33.44%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.52
Upside: -1.32%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $170.38
Upside: +11.52%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.87
Upside: +102.29%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.12
Upside: +36.22%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $36.04
Upside: +2.66%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $57.63
Upside: +12.79%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $205.02
Upside: +21.94%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.88
Upside: +308.16%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,345.27
Upside: -3.37%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $14.87
Upside: -19.30%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $543.95
Upside: +17.66%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $141.61
Upside: +2.39%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $46.96
Upside: -